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Near full-length genomes of 4 unclassiﬁ  ed  HIV-1 
variants infecting patients enrolled in an antenatal cohort 
in Canada were obtained by sequencing. All 4 variants 
showed original recombination proﬁ  les, including A1/A2/J, 
A1/D, and A1/G/J/CRF11_cpx structures. Identiﬁ  cation  of 
these variants highlights the growing prevalence of unique 
recombinant forms of HIV-1 in North America.
H
IV-1 displays extensive genetic diversity. Group M 
includes 9 subtypes and >45 circulating recombinant 
forms (CRFs) (1). In western and central Africa, where the 
highest levels of HIV-1 genetic heterogeneity are observed, 
most subtypes cocirculate along with CRFs and unique re-
combinant forms (URFs). This diversity may complicate 
diagnosis and treatment of HIV infection and represents a 
challenge for vaccine design. In North America, the HIV-1 
epidemic is dominated by subtype B; non-B subtypes are 
infrequently reported (2,3). Nonetheless, recent studies 
have shown a growing prevalence of non-B variants (4,5). 
In 2005, Akouamba et al. reported high levels of HIV-1 
genetic diversity among participants in the Centre Maternel 
et Infantile sur le SIDA (CMIS) antenatal cohort of Centre 
Hospitalier Universitaire (CHU) Sainte-Justine, Montreal, 
Canada (6). Of these patients, 44 of 103 were infected with 
non-B subtypes, including 4 variants that failed to group 
within known subtypes in phylogenetic analyses (6). We 
performed near full-length genomic sequencing to charac-
terize these 4 unassigned variants.
The Study
All 4 patients were newcomers to Canada from sub-
Saharan Africa who received prenatal care at CMIS during 
1999–2003 (6). Patient TV721 emigrated from the Demo-
cratic Republic of Congo, TV749 from Congo, and TV725 
and TV919 from Rwanda. HIV-1 viral loads at study entry, 
measured by the Versant HIV-1 RNA 3.0 assay (bDNA) 
(Bayer, Pittsburgh, PA, USA), with a limit of detection of 
50 RNA copies/mL plasma, were 164–23,369 RNA copies/
mL plasma. CD4+ T cell counts ranged from198 cells/mm3 
to 816 cells/mm3 (Table). Standardized clinical follow-up, 
including antiretroviral prophylaxis and treatment, was 
provided to all women and their children. This study was 
conducted according to the guidelines of the Ethics Review 
Board of CHU Sainte-Justine.
Viral RNA was extracted from serum and ampliﬁ  ed by 
using custom-designed primers and the QIAGEN OneStep 
reverse transcription–PCR (QIAGEN, Mississauga, ON, 
Canada) (sequences available on request). For each iso-
late, 14–20 amplicons spanning the complete genome were 
generated and subcloned into pCR 2.1 TOPO (Invitrogen, 
Carlsbad, CA, USA). For each amplicon, we sequenced 
3–10 independent clones (Beckman-Coulter, Palo Alto, 
CA, USA). Chromatograms were edited with Chromas 
version 1.45 (Technelysium, Southport, Queensland, Aus-
tralia). Overlapping segments were aligned by using Clust-
alX version 1.81 (7) and assembled manually. Consensus 
sequences were generated by selecting the most frequent 
nucleotide at each position. We performed bootscan analy-
ses according to the neighbor-joining method and Kimura 
2-parameter distances using a 300-nt window and 10-nt 
increments (Simplot 3.5.1) (8). These parameters allow ac-
curate localization of recombination breakpoints in HIV-1 
recombinants (9). We computed phylogenetic reconstruc-
tions based on the neighbor-joining method and Kimura 
2-parameter distances by using MEGA4 (10) to conﬁ  rm 
recombinant structures. Bootstrap values >80% were con-
sidered signiﬁ  cant.
Complete HIV-1 genomic sequences were obtained 
from patients TV721 (9,794 nt) and TV749 (9,791 nt). Ge-
nomic coverage of 79.3% and 91.6% was achieved for pa-
tients TV725 (7,763 nt) and TV919 (8,905 nt), respective-
ly. On the basis of HXB2 numbering (1), missing regions 
were located between positions 545–1411 and between 
6946–7930 for patient TV725, and between positions 7138 
and 7834 for patient TV919. Screening of HIV-1 genomic 
sequences from patient TV721 with the HIVdb Genotypic 
Resistance Interpretation Algorithm (http://hivdb6.stan-
ford.edu/asi/deployed/HIVdb.html) showed minor resis-
tance mutations to protease inhibitors (L10I) and integrase 
inhibitors (I203M). Mutations associated with minor re-
sistance to protease inhibitors (L10I) and non-nucleoside 
reverse transcription inhibitors (E138A) were detected in 
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high-level resistance to delavirdine (P236L) was detect-
ed in patient TV725. In contrast, sequences from patient 
TV749 did not show mutations associated with resistance 
to antiretroviral agents (11). Previous subtyping, based 
on phylogenetic analyses of pol gene sequences, showed 
that sequences from patients TV721 and TV749 grouped 
together (100% bootstrap) but only loosely with clade J ref-
erences (61% bootstrap); sequences from patients TV725 
and TV919 grouped outside all major clades (6). Bootscan 
analysis showed complex recombinant structures for all 4 
full-length or near full-length genomes (Figure). Sequences 
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Table. Virologic and immunologic parameters in patients participating in antenatal cohort, Canada* 
Patient Age, y CD4 count, cells/mm
3 Viral load, RNA copies/mL Antiretroviral treatment
TV721 33.2 210 164 AZT-3TC-NVP
TV725 30.1 816 739 None
TV749 34.1 198 23,369 AZT-3TC-NFV
TV919 34.0 420 1,910 AZT-3TC-NFV
*AZT, zidovudine; 3TC, lamivudine; NVP, nevirapine; NFV, nelfinavir.  
Figure. Genetic organization and recombination breakpoints in HIV-1 genomic sequences isolated from patients TV721 (A), TV725 (B), 
TV749 (C), and TV919 (D). Nucleotide sequences were submitted to GenBank (accession nos. HM215249–HM215252). Similarity plots 
were produced with Simplot version 3.5.1 (http://sray.med.som.jhmi.edu/SCRoftware/simplot) by using windows of 500 nt and increments 
of 50 nt to guide the choice of reference sequences used for bootscanning (8). Bootscan analyses were then performed according to 
the neighbor-joining method and Kimura 2-parameter distances. The size of the sliding window was set at 300 nt with 10-nt increments 
(9). Reference sequences used were subtype A1: A1.AU.03 (DQ676872), A1.KE.94 (AF004885), A1.RW.92 (AB253421); subtype A2: 
A2.CD.97 (AF286238), A2.CY.94 (AF286237); subtype D: D.CD.83.ELI (K03454), D.CM.01 (AY371157), D.TZ.01 (AY253311); subtype 
G: G.BE.96 (AF084936), G.KE.93 (AF061641), G.NG.92 (U88826); subtype J: J.CD.97 (EF614151), J.SE.94 (AF082394), J.SE.93 
(AF082395); and CRF11_cpx: 11_cpx.CM.95 (AF492624). Phylogenetic reconstructions based on the neighbor-joining method and the 
Kimura 2-parameter distance model were computed by MEGA4 (10) and used to conﬁ  rm the structures of the recombinants. Bootstrap 
values >80% (500 replicates) were considered signiﬁ   cant. Vertical dashed lines indicate the position of recombination breakpoints. 
Numbering of residues is based on the sequence of HIV-1 HXB2 (GenBank accession no. K03455).Novel HIV-1 Recombinants
derived from patients TV721 and TV749 comprised regions 
from subtype J but were also similar to subtypes A1 and 
A2 (Figure). Examination of the homology, position, and 
sharing of recombination breakpoints suggests that HIV-1 
isolates infecting patients TV721 and TV749 may be close-
ly related recombinants, perhaps resulting from common-
source transmission or representing a novel CRF or URF. 
Reciprocal bootscan analyses that included subtypes A1, 
A2, and J supported this assessment (data not shown). 
However, a review of the medical ﬁ  les and case histories of 
patients TV721 and TV749 did not conﬁ  rm epidemiologic 
relatedness. Although multiple CRFs and URFs contain 
segments related to subtypes A and J, sequences from pa-
tients TV721 and TV749 are 2 of only 3 full-length HIV-1 
genomes reported that exclusively comprise sequences 
related to subtypes A and J (12). The genomic structure 
of 98BW21.17 resembles that of sequences from patients 
TV721 and TV749 in terms of chimerism, but the location 
of recombination breakpoints is distinct (data not shown).
Sequences from patients TV725 and TV919 grouped 
outside all major clades in phylogenetic analyses of pol 
gene sequences (6). Bootscan analysis of the HIV-1 strain 
infecting patient TV725 clearly demonstrated that this vari-
ant comprised segments most closely related to subtypes 
A1 and D (Figure). Sequences from patient TV725 display 
a recombination pattern resembling that of CRF35_AD, the 
only other A1/D intersubtype recombinant described, which 
was recently identiﬁ  ed in Kabul, Afghanistan (13). CRF35_
AD and TV725 share A1 backbones, and recombination 
points bordering clade D segments are comparatively close 
(positions 2166–2444 for CRF35_AD and 2133–2360 for 
the isolate infecting patient TV725; positions 2901–3538 
for CFR35_AD and 2897–3659 for TV725). However, 
they differ with respect to a clade D–related segment at po-
sitions 9044–9489 in TV725 (Figure). Finally, analysis of 
TV919 sequences showed complex A1/G/J mosaicism and 
similarities with CRF11_cpx, in terms of clade composi-
tion and localization of recombination breakpoints (14). 
Including the CRF11_cpx reference sequence 95CM1816 
in bootscan analysis highlighted the similarities between 
sequences from patient TV919 and CRF11_cpx (Figure), 
which extends from positions 3227 to 7137 and includes 
segments corresponding to subtypes A1, G, and J. The 
most distinctive difference between the isolate infecting 
patient TV919 and CRF11_cpx started at position 7835; 
the former sequentially clustered with subtypes A1, J, and 
G, CRF11_cpx closely associated with subtypes J, A1, and 
E. Thus, the isolate infecting patient TV919 represents a 
novel A/G/J/CRF11_cpx recombinant. The HIV-1 isolates 
that infected patients TV721, TV725, TV749, and TV919 
had more recombination breakpoints and unclassiﬁ  ed re-
gions than most CRFs and URFs, highlighting their unique 
recombination proﬁ  les and structural complexity.
Conclusions
We identiﬁ   ed novel HIV-1 recombinants infecting 
pregnant women in Montreal. None of the 4 patients trans-
mitted HIV-1 to their children. No evidence was found 
that these particular variants currently circulate within 
the Canadian population. Thus, the HIV-1 isolates infect-
ing patients TV721, TV725, TV749, and TV919 must be 
construed as URFs. In North America, only 1 URF, also 
isolated in Montreal, was characterized by near full-length 
genomic sequencing (5). Given the ongoing movement of 
the population from areas where the disease is endemic into 
regions in which subtype B predominates, reports of nov-
el HIV-1 recombinants are likely to increase and include 
complex mosaic genomes. Biological properties of recom-
binant subtypes might differ from those of other clades, 
particularly in terms of HIV disease progression (15) and 
drug resistance. In terms of public health, antenatal cohorts 
represent unique sentinel sites to monitor the emergence of 
novel HIV-1 variants, including complex mosaic recombi-
nants, in countries where their prevalence is low.   
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